Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and...
ZURICH - Biogen Inc should slash the price of its spinal muscular atrophy drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.
Boston-based ICER has been looking at Biogen’s Spinraza and Novartis’ Zolgensma since last year. The extremely high cost of new treatments for rare conditions has placed SMA at the center of the drug affordability debate. SMA can lead to paralysis, breathing difficulty and death within months for babies born with the most serious Type I form of the disease. It is the leading genetic cause of death in infants.
“The price for Zolgensma should be lower than the hypothetical $4-$5 million price the manufacturer has suggested could be justified,” ICER concluded. Zolgensma would be worth $310,000 to $900,000 for Type 1 SMA patients based on the QALY assessment, or $710,000 to $1.5 million using the LYG calculation, ICER said.
“The value measures and thresholds employed by ICER in this report are designed around the status quo of chronic care management and cannot possibly capture the full benefits of disease-modifying treatments delivered as a one-time administration,” Novartis said in a statement.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bitcoin soars 20 percent, mystery buyer seen as catalystBitcoin burst to its highest level in almost five months on Tuesday, sending sma...
Read more »
How cutting Obamacare could help drug companies keep prices highPresident Trump has promised to take on big drug companies and drug pricing, but he’s also promised to take out Obamacare. Ali Velshi and Stephanie Ruhle break down how cutting Obamacare could help companies keep prices high. Senator Ron Wyden joins the conversation with his plans to make prescription drugs more affordable.
Read more »
Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rulesNovartis AG must face a U.S. government lawsuit accusing it of paying millions o...
Read more »
New drug represents 'paradigm shift' in treatment of acute myeloid leukemiaCNN News, delivered. Select from our newsletters below and enter your email to subscribe.
Read more »
How this cancer drug has shown promise for the treatment of dementiaNot all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another.
Read more »
U.S. lawmakers urge sanctions over China's treatment of Muslim minorityA bipartisan group of U.S. lawmakers on Wednesday faulted the Trump administrati...
Read more »
A Far-Right Group Linked To The Christchurch Shooter Staged An Anti-Immigrant Protest In ParisGeneration Identity is facing fresh calls to be banned in France, days after Austria said it could try to dissolve the group.
Read more »
Measles cases so far this year in the U.S. already surpass the 2018 totalThe number of U.S. measles cases through the first three months of this year have surpassed the count for all of 2018, health officials say.
Read more »
BlackPink: The All-Girl K-Pop Group Following BTS's Footsteps And Taking Over The U.S.The first girl group of any country to land on Forbes Asia’s 30 Under 30 list, BLACKPINK has set the bar for female K-pop acts on the Billboard 200 and Hot 100 charts and is driving a frenzy among its “Blink” fans over its debut world tour later this month.
Read more »